Table 2. Summarization of Bioengineered AH Vaults’ Ability to Selectively Associate with a Small Sample Set of Therapeutic Compounds with Different Physicochemical Properties via Noncovalent, Reversible Association within a Novel Internalized Lipophilic Core Microenvironment Generated by the Covalent Attachment of a Unique Amphipathic α-Helix Peptide (NS5A1-31) to the MVP.

therapeutic compound	solubilityH2O (mg/mL)	LogP (octanol/water)	loading condition	drug:vault starting ratio (M)	drug:vault ending ratio (M)	detection method
doxorubicin (580 g/mol)	50	1.27 (PubChem)	0.5 h at 4 °C, 20 h centrifugation	10 μg:1000 μg (129:1)	none detected	UV/vis spectra, DOXε480nn = 11 500 M–1 cm–1
amphotericin B (924 g/mol)	0.75	0.8 (DrugBank)	0.5 h at 4 °C, 20 h centrifugation	10 μg:1000 μg (80:1)	5.6 ng:l μg (45:1)	UV/vis spectra, AMBε406 nm = 150 000 M–1 cm–1
			0.5 h at 4 °C, 5 min spin column	10 μg:100 μg (815:1)	149.2 ng:l μg (1213:1)	UV/vis spectra, AMBε406 nm = 150 000 M–1 cm–1
			0.5 h at 4 °C, 5 min spin column	50 μg:100 μg (4075:1)	254.7 ng:l μg (2071:1)	UV/vis spectra, AMBε406 nm = 150 000 M–1 cm–1
all-trans retinoic acid (300 g/mol)	insoluble	6.30 (DrugBank)	0.5 h at 4 °C, 20 h centrifugation	10 μg:1000 μg (250:1)	7.3 ng:l μg (182:1)	UV/vis spectra, ATRAε350 nm = 44,300 M–1 cm–1
bryostatin 1 (905 g/mol)	insoluble	4.25–5.40 (predicted, ChEMBL and ChemSpyder)	0.5 h at 4 °C, 1 h centrifugation	1 μg:100 μg (83:1)	13.4 ng:l μg (83:1)	mass spec (MRM-LC-MS/MS)